Effects of interleukin-11 on carboplatin-induced thrombocytopenia in rats and in combination with stem cell factor

Int J Hematol. 1997 Jun;65(4):397-404. doi: 10.1016/s0925-5710(96)00573-7.

Abstract

The effects of interleukin-11 (IL-11) which stimulates megakaryopoiesis and thrombopoiesis and/or stem cell factor (SCF) which stimulates multiple lineage cells in the peripheral blood by an increase in marrow cellularity on hematopoietic suppression in carboplatin (CBDCA)-treated rats were determined. CBDCA was administered to rats at a dose of 35 mg/kg as a single intraperitoneal bolus on day 0. IL-11 (20 micrograms/day) was given subcutaneously for 10 days from day 5 after CBDCA treatment. IL-11 ameliorated the suppression of hematopoiesis in rats treated with CBDCA. Especially, the production of the platelets was stimulated by IL-11 more markedly than that of cells of other lineages. However, the combination of SCF and IL-11 intensified the CBDCA-induced suppression of hematopoiesis. These findings may be helpful in the design of future therapies to prevent or treat thrombocytopenia induced by chemotherapy.

MeSH terms

  • Animals
  • Antineoplastic Agents / toxicity*
  • Carboplatin / toxicity*
  • Hematopoiesis / drug effects
  • Interleukin-11 / pharmacology*
  • Interleukin-11 / toxicity
  • Male
  • Rats
  • Rats, Sprague-Dawley
  • Recombinant Proteins / pharmacology
  • Recombinant Proteins / toxicity
  • Stem Cell Factor / pharmacology*
  • Stem Cell Factor / toxicity
  • Thrombocytopenia / blood
  • Thrombocytopenia / chemically induced*
  • Thrombocytopenia / prevention & control

Substances

  • Antineoplastic Agents
  • Interleukin-11
  • Recombinant Proteins
  • Stem Cell Factor
  • Carboplatin